KUALA LUMPUR, Nov 22 (Bernama) -- Adagene Inc (Adagene), a company transforming the discovery and development of antibody-based therapies, has appointed Cuong Do as an independent director.
In a statement, the company said Do will also serve as an audit committee member.
Adagene co-founder, chief executive officer (CEO) and board chairman, Dr Peter Luo said he is delighted to welcome Do to the board as the company approaches significant milestones and engage in business development activities with major strategic considerations.
Meanwhile, Do said he was excited to join the Adagene board and doing what he can to help advance the programmes to help the patients.
“Adagene has ground-breaking innovations that can improve the efficacy and safety of immunotherapies.
“I look forward to working with the company and our partners to advance the programmes and benefit patients,” he said.
Do is also the president and CEO of BioVie Inc, a clinical-stage company developing innovative therapies for Alzheimers, Parkinson's and refractory ascites.
Prior to BioVie, he was the president of Samsung’s Global Strategy Group where he helped to set the strategic direction for Samsung Group’s diverse business portfolio, including the growth of its biologics businesses.
BERNAMA provides up-to-date authentic and comprehensive news and information which are disseminated via BERNAMA Wires; www.bernama.com; BERNAMA TV on the Astro 502, unifi TV 631 and MYTV 121 IFLIX channels and BERNAMA Radio on the FM93.9 (Klang Valley), FM107.5 (Johor), FM107.9 (Kota Kinabalu) and RM100.9 (Kuching) frequencies.
Follow us on social media :
Facebook : @bernamaofficial, @bernamatv, @bernamaradio
Twitter : @bernama.com, @BernamaTV, @bernamaradio
Instagram : @bernamaofficial, @bernamatvofficial, @bernamaradioofficial
TikTok : @bernamaofficial